Multiple primary tumours: challenges and approaches, a review.
Alexia Vogt,Alexia Vogt,Sabine Schmid,Karl Heinimann,Harald Frick,Christian Herrmann,Thomas Cerny,Aurelius Omlin,Aurelius Omlin +8 more
- Vol. 2, Iss: 2
Reads0
Chats0
TLDR
From a clinical standpoint, clinical situations when multiple primaries should be suspected and ruled out in a patient are discussed and general principles and possible treatment strategies for patients with synchronous and metachronous multiple primary tumours are highlighted.Abstract:
When in a patient more than one tumour in the same or a different organ is diagnosed, multiple primary tumours may be present. For epidemiological studies, different definitions of multiple primaries are used with the two main definitions coming from the project Surveillance Epidemiology and End Results and the International Association of Cancer Registries and International Agency for Research on Cancer. The differences in the two definitions have to be taken into consideration when reports on multiple primaries are analysed. In this review, the literature on multiple primaries is reviewed and summarised. Overall, the frequency of multiple primaries is reported in the range of 2-17%. Aetiological factors that may predispose patients to multiple primaries can be grouped into host related, lifestyle factors and environmental influences. Some of the most common cancer predisposition syndromes based on a clinical presentation are discussed and the relevant genetic evaluation and testing are characterised. Importantly, from a clinical standpoint, clinical situations when multiple primaries should be suspected and ruled out in a patient are discussed. Furthermore, general principles and possible treatment strategies for patients with synchronous and metachronous multiple primary tumours are highlighted.read more
Citations
More filters
Journal ArticleDOI
The relative risk of second primary cancers in Switzerland: a population-based retrospective cohort study.
Anita Feller,Katarina L. Matthes,Andrea Bordoni,Christine Bouchardy,Jean-Luc Bulliard,Jean-Luc Bulliard,Christian Herrmann,Isabelle Konzelmann,Manuela Maspoli,Mohsen Mousavi,Sabine Rohrmann,Katharina Staehelin,Volker Arndt,Volker Arndt +13 more
TL;DR: Swiss cancer survivors have an increased risk of developing a SPC compared to the general population, particularly patients first diagnosed before age 50 and those surviving more than 10 years.
Journal ArticleDOI
Utility of a gel stand-off pad in the detection of Doppler signal on focal nodular lesions of the skin
Antonio Corvino,Fabio Sandomenico,Fabio Corvino,Maria Raffaela Campanino,Francesco Verde,Francesco Giurazza,Domenico Tafuri,Orlando Catalano +7 more
TL;DR: The use of a gel stand-off pad allows the detection of otherwise-missed peri- or intra-lesional flow signals on Doppler imaging, increasing the diagnostic role of this technique in differential diagnosis of superficial lesions.
Journal ArticleDOI
Prognostic impact of a past or synchronous second cancer in diffuse large B cell lymphoma.
Kazuna Tanba,Yoshiaki Chinen,Hitoji Uchiyama,Nobuhiko Uoshima,Kazuho Shimura,Shin-ichi Fuchida,Miki Kiyota,Mitsushige Nakao,Yuji Shimura,Tsutomu Kobayashi,Shigeo Horiike,Katsuya Wada,Chihiro Shimazaki,Hiroto Kaneko,Yutaka Kobayashi,Masafumi Taniwaki,Junya Kuroda +16 more
TL;DR: A retrospective analysis of 809 DLBCL patients diagnosed histologically and treated between January 2006 and February 2016 at institutes in the Kyoto Clinical Hematology Study Group found no significant difference in disease stage or international prognostic index (IPI)defined disease risk between patients with and without MPM.
Journal ArticleDOI
Cell membrane–camouflaged liposomes for tumor cell–selective glycans engineering and imaging in vivo
TL;DR: Zhang et al. as mentioned in this paper constructed pH-responsive azidosugar liposomes camouflaged with natural cancer-cell membrane for tumor cell-selective glycan engineering.
References
More filters
Journal ArticleDOI
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Brandon Luber,Nilofer S. Azad,Daniel A. Laheru,Barbara A. Biedrzycki,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Steven M. Duffy,Richard M. Goldberg,Richard M. Goldberg,Albert de la Chapelle,Albert de la Chapelle,Minori Koshiji,Feriyl Bhaijee,Thomas Huebner,Ralph H. Hruban,Laura D. Wood,Nathan Cuka,Drew M. Pardoll,Nickolas Papadopoulos,Kenneth W. Kinzler,Shibin Zhou,Toby C. Cornish,Janis M. Taube,Robert A. Anders,James R. Eshleman,Bert Vogelstein,Luis A. Diaz +36 more
TL;DR: This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab, and high somatic mutation loads were associated with prolonged progression-free survival.
Journal ArticleDOI
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
J. Ferlay,Eva Steliarova-Foucher,Joannie Lortet-Tieulent,Sonia Rosso,Jan Willem Coebergh,Harry Comber,David Forman,Freddie Bray +7 more
TL;DR: Up-to-date estimates of the cancer burden in Europe alongside the description of the varying distribution of common cancers at both the regional and country level provide a basis for establishing priorities to cancer control actions in Europe.
Cancer Facts & Figures 2004
Paul Betts,Brenda Mokry,David R Risser,Nancy S. Weiss,Melanie Williams,Elizabeth Sjoberg,Mark Clanton,Lawrence S Frankel,Lewis E. Foxhall,Lynn Hancock,Allen Henderson,Karen B Heusinkveld,Jon Hornaday,Mark Redrow,Jessica Albano +14 more
TL;DR: The number of new cancer cases for 2010, excluding basal and squamous cell skin cancers and in situ carcinomas except urinary bladder, is estimated as a rough guide and should be interpreted with caution.
Journal ArticleDOI
PD-1 blockade in tumors with mismatch repair deficiency.
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Nilofer S. Azad,Daniel A. Laheru,Ross C. Donehower,Brandon Luber,Todd S. Crocenzi,George A. Fisher,Steve M Duffy,James J. Lee,Minori Koshiji,James R. Eshleman,Robert A. Anders,Bert Vogelstein,Luis A. Diaz +19 more
TL;DR: MM status predicts clinical benefit of immune checkpoint blockade with pembrolizumab, and high total somatic mutation loads were associated with PFS.
Journal ArticleDOI
Hereditary Colorectal Cancer
TL;DR: This article provides an in-depth review of the two most common forms of familial colorectal cancer, and the identification of those at risk and the use of appropriate colonoscopic screening.